United Therapeutics Shares Outstanding 2006-2018 | UTHR

United Therapeutics shares outstanding from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
United Therapeutics Annual Shares Outstanding
(Millions of Shares)
2017 45
2016 47
2015 51
2014 54
2013 53
2012 53
2011 59
2010 60
2009 56
2008 46
2007 45
2006 48
2005 50
United Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 44
Q2 2018 43
Q1 2018 44
Q4 2017 45
Q3 2017 44
Q2 2017 45
Q1 2017 46
Q4 2016 47
Q3 2016 46
Q2 2016 47
Q1 2016 49
Q4 2015 51
Q3 2015 50
Q2 2015 52
Q1 2015 47
Q4 2014 54
Q3 2014 47
Q2 2014 53
Q1 2014 57
Q4 2013 53
Q3 2013 54
Q2 2013 53
Q1 2013 52
Q4 2012 53
Q3 2012 54
Q2 2012 54
Q1 2012 55
Q4 2011 59
Q3 2011 61
Q2 2011 63
Q1 2011 63
Q4 2010 60
Q3 2010 60
Q2 2010 60
Q1 2010 60
Q4 2009 56
Q3 2009 58
Q2 2009 53
Q1 2009 54
Q4 2008 46
Q3 2008 51
Q2 2008 49
Q1 2008 48
Q4 2007 45
Q3 2007 45
Q2 2007 44
Q1 2007 43
Q4 2006 48
Q3 2006 50
Q2 2006 51
Q1 2006 51
Q4 2005 50
Q3 2005 51
Q2 2005 50
Q1 2005 49
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $4.873B $1.725B
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Stock Name Country Market Cap PE Ratio
Shire (SHPG) Ireland $55.305B 11.85
Zoetis (ZTS) United States $45.369B 31.06
Grifols (GRFS) Spain $14.134B 17.25
Tilray (TLRY) United States $10.566B 0.00
Neurocrine Biosciences (NBIX) United States $9.340B 2060.00
Jazz Pharmaceuticals (JAZZ) Ireland $8.960B 12.86
Ionis Pharmaceuticals (IONS) United States $6.913B 0.00
Nektar Therapeutics (NKTR) United States $6.402B 9.18
Impax Laboratories (AMRX) United States $5.957B 31.68
Sage Therapeutics (SAGE) United States $5.694B 0.00
Catalent (CTLT) United States $5.515B 23.13
Loxo Oncology (LOXO) United States $4.943B 0.00
Taro Pharmaceutical Industries (TARO) Israel $4.039B 14.96
FibroGen (FGEN) United States $3.347B 0.00
Endo (ENDP) Ireland $2.957B 4.53
USANA Health Sciences (USNA) United States $2.872B 24.44
Madrigal Pharmaceuticals (MDGL) United States $2.871B 0.00
Heron Therapeutics (HRTX) United States $2.149B 0.00
Xencor (XNCR) United States $2.071B 0.00
Aerie Pharmaceuticals (AERI) United States $2.030B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.987B 268.56
Endocyte (ECYT) United States $1.933B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.726B 0.00
PTC Therapeutics (PTCT) United States $1.632B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.487B 18.18
TESARO (TSRO) United States $1.487B 0.00
Zogenix (ZGNX) United States $1.465B 0.00
Corcept Therapeutics (CORT) United States $1.463B 21.48
Theravance Biopharma (TBPH) Cayman Islands $1.419B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.376B 0.00
Portola Pharmaceuticals (PTLA) United States $1.356B 0.00
Esperion Therapeutics (ESPR) United States $1.348B 0.00
Tricida (TCDA) United States $1.193B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.129B 0.00
TherapeuticsMD (TXMD) United States $1.120B 0.00
ImmunoGen (IMGN) United States $0.841B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.784B 0.00
Radius Health (RDUS) United States $0.684B 0.00
Karyopharm Therapeutics (KPTI) United States $0.651B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.635B 0.00
Flexion Therapeutics (FLXN) United States $0.614B 0.00
GlycoMimetics (GLYC) United States $0.528B 0.00
Collegium Pharmaceutical (COLL) United States $0.527B 0.00
ChemoCentryx (CCXI) United States $0.473B 37.44
Dova Pharmaceuticals (DOVA) United States $0.467B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.455B 0.00
Odonate Therapeutics (ODT) United States $0.451B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.450B 0.00
Xeris Pharmaceuticals (XERS) United States $0.448B 0.00
Akebia Therapeutics (AKBA) United States $0.441B 0.00
Dermira (DERM) United States $0.441B 0.00
ArQule (ARQL) United States $0.434B 0.00
OptiNose (OPTN) United States $0.427B 0.00
Aquestive Therapeutics (AQST) United States $0.415B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.406B 23.90
Siga Technologies (SIGA) United States $0.396B 0.00
Forty Seven (FTSV) United States $0.395B 0.00
Zafgen (ZFGN) United States $0.387B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.377B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.373B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.360B 0.00
Mast Therapeutics (SVRA) United States $0.346B 0.00
Depomed (ASRT) United States $0.344B 12.81
Minerva Neurosciences (NERV) United States $0.328B 0.00
KalVista Pharmaceuticals (KALV) United States $0.318B 0.00
Tapimmune (MRKR) United States $0.315B 0.00
Aratana Therapeutics (PETX) United States $0.309B 0.00
Aclaris Therapeutics (ACRS) United States $0.305B 0.00
Concert Pharmaceuticals (CNCE) United States $0.295B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.285B 0.00
Majesco Entertainment (PTE) United States $0.281B 0.00
CASI Pharmaceuticals (CASI) United States $0.279B 0.00
Translate Bio (TBIO) United States $0.270B 0.00
IMV INC (IMV) Canada $0.243B 0.00
Affimed (AFMD) Germany $0.240B 0.00
ElectroCore (ECOR) United States $0.237B 0.00
Opexa Therapeutics (ACER) United States $0.235B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.231B 0.00
MEI Pharma (MEIP) United States $0.219B 0.00
Ocular Therapeutix (OCUL) United States $0.217B 0.00
Lannett Co Inc (LCI) United States $0.215B 1.88
Aldeyra Therapeutics (ALDX) United States $0.215B 0.00
Tyme Technologies (TYME) United States $0.212B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.201B 0.00
Galectin Therapeutics (GALT) United States $0.198B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.194B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.193B 0.00
Calithera Biosciences (CALA) United States $0.192B 0.00
Redhill Biopharma (RDHL) Israel $0.187B 0.00
Neon Therapeutics (NTGN) United States $0.185B 0.00
Ardelyx (ARDX) United States $0.183B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.181B 0.00
Nature's Sunshine Products (NATR) United States $0.169B 0.00
ContraFect (CFRX) United States $0.168B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.165B 0.00
Molecular Templates (MTEM) United States $0.162B 0.00
MediWound (MDWD) Israel $0.154B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.152B 0.00
Recro Pharma (REPH) United States $0.150B 0.00
DURECT (DRRX) United States $0.148B 0.00
Melinta Therapeutics (MLNT) United States $0.147B 0.00
Jounce Therapeutics (JNCE) United States $0.146B 0.00
Champions Oncology (CSBR) United States $0.145B 0.00
Adherex Technologies (FENC) United States $0.135B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.128B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.124B 0.00
ProNAi Therapeutics (SRRA) Canada $0.121B 0.00
Cardiome Pharma (CORV) Canada $0.110B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.109B 0.00
Rafael Holdings (RFL) United States $0.101B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.101B 0.00
CTI BioPharma (CTIC) United States $0.097B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.095B 0.00
Achaogen (AKAO) United States $0.092B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.090B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.081B 0.00
Iterum Therapeutics (ITRM) Ireland $0.080B 0.00
Otonomy (OTIC) United States $0.075B 0.00
Infinity Pharmaceuticals (INFI) United States $0.075B 0.00
Neos Therapeutics (NEOS) United States $0.073B 0.00
BioLineRx (BLRX) Israel $0.072B 0.00
Nivalis Therapeutics (ALPN) United States $0.072B 0.00
Natural Alternatives (NAII) United States $0.070B 7.87
Immune Design (IMDZ) United States $0.066B 0.00
Forward Pharma (FWP) Denmark $0.066B 0.00
Novan (NOVN) United States $0.065B 0.00
Ampio Pharmaceuticals (AMPE) United States $0.064B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.064B 39.48
Actinium Pharmaceuticals (ATNM) United States $0.063B 0.00
Genocea Biosciences (GNCA) United States $0.059B 0.00
Capnia (SLNO) United States $0.046B 0.00
Avenue Therapeutics (ATXI) United States $0.044B 0.00
Trillium Therapeutics (TRIL) Canada $0.043B 0.00
SCYNEXIS (SCYX) United States $0.042B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.041B 0.00
Mannatechorporated (MTEX) United States $0.040B 0.00
KemPharm (KMPH) United States $0.039B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.038B 0.00
Heat Biologics (HTBX) United States $0.036B 0.00
ProPhase Labs (PRPH) United States $0.035B 3.88
Lipocine (LPCN) United States $0.034B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.034B 0.00
Onconova Therapeutics (ONTX) United States $0.029B 0.00
HANCOCK JAFFE (HJLI) United States $0.026B 0.00
IsoRay (ISR) United States $0.026B 0.00
Can-Fite Biopharma (CANF) Israel $0.026B 0.00
Biomerica (BMRA) United States $0.025B 0.00
NanoViricides (NNVC) United States $0.024B 0.00
Xenetic Biosciences (XBIO) United States $0.024B 0.00
Jaguar Animal Health (JAGX) United States $0.022B 0.00
Citius Pharmaceuticals (CTXR) United States $0.022B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.021B 0.00
Pain Therapeutics (PTIE) United States $0.020B 0.00
Cyanotech (CYAN) United States $0.020B 0.00
ESSA Pharma (EPIX) Canada $0.020B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.020B 7.05
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.019B 0.00
Aviragen Therapeutics (VXRT) United States $0.018B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.017B 0.00
Aradigm (ARDM) United States $0.017B 0.00
Shineco (TYHT) China $0.016B 1.65
Eyegate Pharmaceuticals (EYEG) United States $0.014B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.013B 0.00
Regulus Therapeutics (RGLS) United States $0.013B 0.00
Skyline Medical (AIPT) United States $0.013B 0.00
Midatech Pharma (MTP) United Kingdom $0.011B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.011B 0.00
Apricus Biosciences (APRI) United States $0.009B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
Bio-Path Holdings (BPTH) United States $0.006B 0.00
PharmAthene (ALT) United States $0.006B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.006B 0.00
Bio Blast Pharma (ORPN) Israel $0.005B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.004B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.004B 0.00
Intellipharmaceutics (IPCI) Canada $0.002B 0.00
RXi Pharmaceuticals (RXII) United States $0.002B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00